2018
Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors
O'Connor JM, Seidl‐Rathkopf K, Torres AZ, You P, Carson KR, Ross JS, Gross CP. Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. The Oncologist 2018, 23: 1388-1390. PMID: 30012876, PMCID: PMC6291337, DOI: 10.1634/theoncologist.2017-0673.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAnti-PD1 agentsAnti-PD1 treatmentImmune checkpoint inhibitorsCheckpoint inhibitorsDeath-1 immune checkpoint inhibitorPrior anticancer therapyDeath protein 1Cell lung cancerCommunity-based cohortAdvanced-stage cancerRenal cell carcinomaSex-based disparitiesSystemic treatmentCell carcinomaLung cancerMultivariable modelObservational studyHigher oddsStage cancerRace-based disparitiesPatient careAnticancer therapyProtein 1Patients
2017
Racial disparities in the use of programmed death-1 checkpoint inhibitors.
O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.Peer-Reviewed Original ResearchDeath-1 checkpoint inhibitorsElectronic health record databaseLines of therapySystemic therapyCheckpoint inhibitorsCancer clinicRacial disparitiesAdvanced non-small cell lung cancerNon-small cell lung cancerMetastatic renal cell carcinomaAnti-PD1 treatmentCell lung cancerRenal cell carcinomaHealth record databaseSignificant racial disparitiesNew cancer drugsSquamous histologyStudy drugReal-world practiceAdvanced melanomaTherapy linesWhite patientsMale sexCell carcinomaLung cancer